Abstract
Reactive oxygen species (ROS) are produced in all mammalian cells as a result of normal cellular metabolism and due to the activation of oxidant-producing enzymes in response to exogenous stimuli. The balance between ROS production and antioxidant defenses determines the degree of oxidative stress. Generation of ROS has been associated with cell signaling, stress responses, cell proliferation, aging and cancer development. The ability of ROS to induce cellular damage and to cause cell death opens the possibility to exploit this property in the treatment of cancer through a free radical-mediated mechanism.
Keywords: ros, b cells, lymphoproliferative disorders, rituximab, 2-methoxyoestradiol, imexon, arsenic trioxide 1, 4- benzodiazepine
Current Pharmaceutical Design
Title: Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species
Volume: 10 Issue: 8
Author(s): Neus Villamor, Emili Montserrat and Dolors Colomer
Affiliation:
Keywords: ros, b cells, lymphoproliferative disorders, rituximab, 2-methoxyoestradiol, imexon, arsenic trioxide 1, 4- benzodiazepine
Abstract: Reactive oxygen species (ROS) are produced in all mammalian cells as a result of normal cellular metabolism and due to the activation of oxidant-producing enzymes in response to exogenous stimuli. The balance between ROS production and antioxidant defenses determines the degree of oxidative stress. Generation of ROS has been associated with cell signaling, stress responses, cell proliferation, aging and cancer development. The ability of ROS to induce cellular damage and to cause cell death opens the possibility to exploit this property in the treatment of cancer through a free radical-mediated mechanism.
Export Options
About this article
Cite this article as:
Villamor Neus, Montserrat Emili and Colomer Dolors, Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species, Current Pharmaceutical Design 2004; 10 (8) . https://dx.doi.org/10.2174/1381612043452848
DOI https://dx.doi.org/10.2174/1381612043452848 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria
Current Pharmaceutical Design Current Advances in Retroviral Gene Therapy
Current Gene Therapy A Review on Synthesis, Anticancer and Antiviral Potentials of Pyrimidine Derivatives
Current Bioactive Compounds Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry Targeting Histone Onco- Modifications Using Plant-Derived Products
Current Drug Targets New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain
Current Drug Discovery Technologies Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem
Cardiovascular & Hematological Disorders-Drug Targets Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology Going 3D – Cell Culture Approaches for Stem Cell Research and Therapy
Current Tissue Engineering (Discontinued) Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma
Current Immunology Reviews (Discontinued) HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology